450 results match your criteria myositis immune-mediated


Peripheral nervous system manifestations of rheumatological diseases.

J Neurol Sci 2021 Mar 27:117421. Epub 2021 Mar 27.

University of Virginia, Department of Neurology, Charlottesville, VA, USA.

Rheumatological diseases result in immune-mediated injury to not only connective tissue, but often components of the peripheral nervous system. These overlap conditions can be broadly categorized as peripheral neuropathies and overlap myositis. The peripheral neuropathies are distinctive as many have unusual presentations such as non-length-dependent, small fiber neuropathies and sensory neuronopathies (both due to dorsal root ganglia dysfunction), multiple mononeuropathies (e. Read More

View Article and Full-Text PDF

The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study.

Front Pharmacol 2021 16;12:635654. Epub 2021 Mar 16.

Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China.

To evaluate the efficacy of tocilizumab (TCZ) in adult patients with refractory immune-mediated necrotizing myopathies (IMNMs) and investigate possible predictive biomarkers of the response to treatment with TCZ. Patients with refractory IMNM were enrolled in this open-label pilot observational study and received intravenous TCZ treatment. The clinical response was assessed after 6 months of TCZ treatment according to the 2016 American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) response criteria for adult dermatomyositis and polymyositis. Read More

View Article and Full-Text PDF

Neurology of inflammatory bowel disease.

J Neurol Sci 2021 Mar 27:117426. Epub 2021 Mar 27.

Serviço de Neurologia, Department of Neurological Sciences and Mental Health, Hospital de Santa Maria - CHULN, Lisboa, Portugal; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal.

Inflammatory bowel diseases (IBD) are chronic inflammatory conditions affecting the digestive system, comprising two main distinctive entities, ulcerative colitis (UC) and Crohn's disease (CD). Besides gastrointestinal manifestations, IBD causes extraintestinal manifestations in the central and peripheral nervous system. The incidence of neurological complications in IBD ranges from 0. Read More

View Article and Full-Text PDF

New Onset of Unilateral Orbital Myositis following Mild COVID-19 Infection.

Ocul Immunol Inflamm 2021 Apr 2:1-2. Epub 2021 Apr 2.

Division of Cornea and Ocular Surface, University of Health Sciences, Haydarpasa Numune Education and Research Hospital, Sadik Eratik Eye Institute, Istanbul, Turkey.

The authors present a case of unilateral orbital myositis of new onset following COVID-19 without a severe course. The patient had been received topical treatment with a preliminary diagnosis of conjunctivitis but no recovery had been noticed. The history revealed that the ocular signs had started 1 week after the COVID-19. Read More

View Article and Full-Text PDF

Granulomatous interstitial polymyositis and intramuscular neuritis in a dog.

Acta Vet Scand 2021 Mar 30;63(1):14. Epub 2021 Mar 30.

Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Ullevålsveien 72, 0454, Oslo, Norway.

Background: Granulomatous myositis is a rare condition in both humans and dogs. In humans it is most frequently related to sarcoidosis, where a concurrent granulomatous neuritis has been reported occasionally. Simultaneous granulomatous myositis and neuritis have been diagnosed previously in dogs (unpublished observations), but have not been studied further. Read More

View Article and Full-Text PDF

COVID-19 and the clinical course of rheumatic manifestations.

Clin Rheumatol 2021 Mar 17. Epub 2021 Mar 17.

Departments of Rheumatology and Research and Development, Russells Hall Hospital, Dudley, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Pensnett Road, Dudley, West Midlands, DY1 2HQ, UK.

The manifestations of COVID-19 have been evolving over time. Various post-COVID-19 syndromes are being recognised. Various viruses have been implicated in the pathogenesis of autoimmune diseases, and we expect a similar outcome with the severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2). Read More

View Article and Full-Text PDF

Immune-mediated neuromuscular complications of graft-versus-host disease.

Muscle Nerve 2021 Mar 2. Epub 2021 Mar 2.

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Introduction/aims: We aimed to describe the clinical phenotype, histopathological findings and overall survival (OS) of the immune-mediated neuromuscular complications of graft-versus-host disease (GVHD).

Methods: We conducted a retrospective chart review of adult patients presenting with immune-mediated neuromuscular complications of GVHD to Mayo Clinic, between April 2013 and July 2018.We collected clinical and laboratory characteristics, histopathological findings, response to treatment and survival data. Read More

View Article and Full-Text PDF

Coexistence of TDP-43 and C5b-9 staining of muscle in a patient with inclusion body myositis.

BMJ Case Rep 2021 Feb 9;14(2). Epub 2021 Feb 9.

Neurology, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA

While sporadic inclusion body myositis (sIBM) is the most commonly acquired inflammatory myopathy above 50 years of age, its refractory response to conventional immunosuppressive treatments raises questions about its perplexing pathogenesis. Muscle biopsy typically reveals major histocompatibility complex I antigens and CD8+ T cell endomysial infiltrates invading non-necrotic muscle fibres early in the disease course with rimmed vacuoles, protein aggregates and amyloid inclusions later in the disease. Transactive response DNA-binding protein-43 (TDP-43), a protein implicated in transcriptional repression in neurodegenerative diseases, is also found in sIBM. Read More

View Article and Full-Text PDF
February 2021

[A Case of Immune-Mediated Necrotizing Myopathy Associated with Primary Sjögren Syndrome].

Brain Nerve 2021 Feb;73(2):183-187

Department of Neurology, Fukuoka University Faculty of Medicine.

A 66-year-old woman visited our hospital complaining of shortness of breath during exertion and progressive weakness in all her limb muscles. On admission, we noted muscle weakness in her trunk and in her proximal limb muscles, although, her muscle MRI showed no remarkable findings. However, her serum CK level (2,747U/L) was above the normal range. Read More

View Article and Full-Text PDF
February 2021

[Clinicopathological Features of Myositis and Necrotizing Myopathy: How to Distinguish between Myositis and Muscular Dystrophy on Muscle Pathology].

Brain Nerve 2021 Feb;73(2):147-159

Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry.

In the field of neurology, idiopathic inflammatory myopathy has been classified into four sub-categories, namely, dermatomyositis, anti-synthetase syndrome, inclusion body myositis, and immune-mediated necrotizing myopathy (IMNM), based upon histological and serological findings. Among them, IMNM has features similar to muscular dystrophy, and it may thus be difficult to differentiate between these two conditions, not only clinically but also pathologically, especially in chronic cases and pediatric patients. This is partly because the main pathological feature of both IMNM and muscular dystrophy is myofiber necrosis and regeneration. Read More

View Article and Full-Text PDF
February 2021

[Immune-Mediated Necrotizing Myopathy: IMNM].

Brain Nerve 2021 Feb;73(2):127-136

Department of Neurology, JA Toride Medical Center.

Immune-mediated necrotizing myopathy (IMNM) is a heterogeneous disease that presents with subacute progressive proximal dominant muscle weakness clinically and prominent necrotic muscle fibers without invasion of inflammatory cells pathologically. IMNM is a disease that exclusively affects skeletal muscles, so the serum creatine kinase level usually increases prominently. It is thought to be an autoimmune disease because of the presence of two autoantibodies, anti-SRP and anti-HMGCR. Read More

View Article and Full-Text PDF
February 2021

Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies.

Ann Clin Transl Neurol 2021 03 8;8(3):571-578. Epub 2021 Feb 8.

Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.

Objective: To define the clinicopathologic features and diagnostic utility associated with anti-cytosolic 5'-nucleotidase 1A (NT5C1A) antibody seropositivity in idiopathic inflammatory myopathies (IIMs).

Methods: Anti-NT5C1A antibody status was clinically tested between 2014 and 2019 in the Washington University neuromuscular clinical laboratory. Using clinicopathologic information available for 593 patients, we classified them as inclusion body myositis (IBM), dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy (IMNM), nonspecific myositis, or noninflammatory muscle diseases. Read More

View Article and Full-Text PDF

Statin-associated anti-HMGCR immune-mediated necrotizing myopathy with dermatomyositis-like features: A case report.

SAGE Open Med Case Rep 2020 29;8:2050313X20984120. Epub 2020 Dec 29.

Division of Rheumatology, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.

Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) immune-mediated necrotizing myopathy is a subtype of idiopathic inflammatory myopathy which may be associated with statin exposure. It presents with severe proximal muscle weakness, high creatine kinase levels and muscle fiber necrosis. Treatment with intravenous immunoglobulins and immunosuppressants is often necessary. Read More

View Article and Full-Text PDF
December 2020

Anti-synthetase syndrome: a rare and challenging diagnosis for bilateral ground-glass opacities-a case report with literature review.

BMC Pulm Med 2021 Jan 6;21(1):11. Epub 2021 Jan 6.

Department of Pulmonology and Critical Care, Jersey Shore University Medical Center, Neptune, NJ, 07753, USA.

Background: Anti-synthetase syndrome (ASS) is an uncommon immune-mediated entity characterized by myositis, interstitial lung disease (ILD), non-erosive arthritis, and less common features such as fever, Raynaud's phenomenon, and skin changes in association with anti-aminoacyl-transfer-RNA antibodies, most commonly anti-Jo-1 antibodies.

Case Presentation: We present a challenging and rare case of ASS-associated ILD presenting with unexplained respiratory symptoms and bilateral infiltrates on chest imaging during the COVID-19 pandemic. High clinical suspicion for ASS with early appropriate therapy with corticosteroids and immunosuppressive agents led to marked clinical improvement. Read More

View Article and Full-Text PDF
January 2021

Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy.

J Oncol 2020 7;2020:8865054. Epub 2020 Dec 7.

Department of Neurology, Hannover Medical School, Hannover, Germany.

Therapy with immune checkpoint inhibitors (ICIs) has improved overall survival and cancer-related morbidity of cancer treatment even in cancer entities with poor prognosis. Since the approval of the first ICI, ipilimumab, for treatment of advanced melanoma by the Food and Drug Administration (FDA) in 2011, the spectrum of indications and approved ICIs has grown, rapidly. Up to now, seven different ICIs for more than 20 indications are available. Read More

View Article and Full-Text PDF
December 2020

Case Report: Orbital Myositis and Myasthenia Gravis as Symptoms of Immune Reconstitution Inflammatory Syndrome in a Patient With Human Immunodeficiency Virus Infection.

Front Immunol 2020 14;11:595068. Epub 2020 Dec 14.

Infectious Diseases Department, The First Affiliated Hospital of China Medical University, Shenyang, China.

We present a case of a 37-year-old man with HIV infection who had been on antiretroviral therapy for one year. He was admitted to our hospital with red and swollen eyes, acute onset progressive exophthalmos, and intermittent diplopia endured for 7 days. His symptoms, exam, and imaging led to a diagnosis of immune reconstitution inflammatory syndrome associated orbital myositis. Read More

View Article and Full-Text PDF
December 2020

Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre.

Rheumatology (Oxford) 2020 Dec 24. Epub 2020 Dec 24.

National Institute for Health Research Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Objective: The current classification criteria for idiopathic inflammatory myopathy (IIM) retain PM as a major disease subgroup. However, evolution in the understanding of IIM has suggested that many of these patients could be better described as having an alternative diagnosis. In the present study, we apply the latest understanding of IIM subtyping to retrospectively review PM diagnoses in a large cohort of IIM patients. Read More

View Article and Full-Text PDF
December 2020

Diagnostic modelling and therapeutic monitoring of immune-mediated necrotizing myopathy: role of electrical myotonia.

Brain Commun 2020 13;2(2):fcaa191. Epub 2020 Dec 13.

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Delayed diagnosis of immunemediated necrotizing myopathy leads to increased morbidity. Patients with the chronic course without 3-hydroxy-3-methylglutaryl-coenzyme-A reductase-IgG or signal recognition particle-IgG are often challenging to diagnose. Immunotherapy response can also be difficult to assess. Read More

View Article and Full-Text PDF
December 2020

Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study.

Lancet Child Adolesc Health 2021 03 16;5(3):167-177. Epub 2020 Dec 16.

Department of Medical Imaging, Division of Pediatric Neuroradiology, Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL USA. Electronic address:

Background: The CNS manifestations of COVID-19 in children have primarily been described in case reports, which limit the ability to appreciate the full spectrum of the disease in paediatric patients. We aimed to identify enough cases that could be evaluated in aggregate to better understand the neuroimaging manifestations of COVID-19 in the paediatric population.

Methods: An international call for cases of children with encephalopathy related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and abnormal neuroimaging findings was made. Read More

View Article and Full-Text PDF

Dual hereditary and immune-mediated neuromuscular diagnoses after cancer immunotherapy.

Muscle Nerve 2021 03 26;63(3):E21-E24. Epub 2020 Dec 26.

Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article and Full-Text PDF

Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy.

Brain Commun 2020 2;2(2):fcaa181. Epub 2020 Nov 2.

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Immune checkpoint inhibitors have revolutionized the landscape of cancer treatment. Alongside their many advantages, they elicit immune-related adverse events, including myopathy, which potentially result in substantial morbidity if not recognized and treated promptly. Current knowledge of immune checkpoint inhibitor-associated myopathy is limited. Read More

View Article and Full-Text PDF
November 2020

[Myositis: From classification to diagnosis].

Rev Med Interne 2020 Nov 25. Epub 2020 Nov 25.

Département de Médecine interne et immunologie clinique, Centre national de référence des maladies neuromusculaires, hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.

Idiopathic inflammatory myopathies, or IIM, are a group of acquired diseases that affect the muscle to a certain extent, and may also affect other organs. They include dermatomyositis, which can affect the muscle eventualy, with a typical skin rash; inclusion body myositis, with a purely muscular expression resulting in a slow progressive deficit; and the former group of "polymyositis", a misnomer that actually includes other categories of IIM, such as immune-mediated necrotizing myopathies, with a severe muscle involvement often presents from the onset of the disease; antisynthetase syndrome, which combines muscle damage, joint involvement and a potentially life-threatening lung disease; and overlapping myositis, which combines muscle damage with other organs involvement connected to another autoimmune disease. The diagnosis of IIM is based on rigorous clinical examination and interrogation, electromyographic data and immunological testing for myositis specific antibodies. Read More

View Article and Full-Text PDF
November 2020

Utilization of myositis antibody-specific panel for diagnosis, treatment, and evaluation of disease progression.

J Community Hosp Intern Med Perspect 2020 Sep 3;10(5):462-465. Epub 2020 Sep 3.

Greater Baltimore Medical Center, Internal Medicine Residency, Towson, MD, USA.

The idiopathic inflammatory myopathies (IIM) are rare sporadic disorders with an overall annual incidence of approximately 1 in 100,000 and with a higher incidence in women. IIM is an autoimmune process leading to muscle inflammation due to a 'dysfunctional adaptive immune response evidenced by cell-mediated myocytoxicity, a high prevalence of autoantibodies and overexpression of Major Histocompatibility (MHC) I and II molecules on the muscle sarcolemma'. These autoimmune processes can be appreciated as inflammatory infiltrates in muscle biopsies. Read More

View Article and Full-Text PDF
September 2020

What is New in Idiopathic Inflammatory Myopathies: Mechanisms and Therapies.

Ann Indian Acad Neurol 2020 Jul-Aug;23(4):458-467. Epub 2020 Apr 13.

Department of Neurology, Dr. L H Hiranandani Hospital, Mumbai, Maharashtra, India.

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of disorders that cause muscle weakness and also have extramuscular manifestations involving various organ systems; namely the lung, skin, heart, and joints. Previously classified broadly as dermatomyositis (DM) and polymyositis now the spectrum of the disease has evolved into more clinical subtypes. There are now five clinicoserological subtypes recognized worldwide DM, antisynthetase syndrome (AS), overlap myositis (OM), immune mediated necrotizing myopathy (IMNM), and inclusion body myositis. Read More

View Article and Full-Text PDF

Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases.

Eur Radiol 2020 Nov 21. Epub 2020 Nov 21.

NMR Laboratory, Neuromuscular Investigation Center, Institute of Myology, Paris, France.

Objectives: Magnetic resonance imaging (MRI) constitutes a powerful outcome measure in neuromuscular disorders, yet there is a broad diversity of approaches in data acquisition and analysis. Since each neuromuscular disease presents a specific pattern of muscle involvement, the recommended analysis is assumed to be the muscle-by-muscle approach. We, therefore, performed a comparative analysis of different segmentation approaches, including global muscle segmentation, to determine the best strategy for evaluating disease progression. Read More

View Article and Full-Text PDF
November 2020

Idiopathic inflammatory myopathy human derived cells retain their ability to increase mitochondrial function.

PLoS One 2020 20;15(11):e0242443. Epub 2020 Nov 20.

Geroscience Center for Brain Health and Metabolism, Santiago, Chile.

Idiopathic Inflammatory Myopathies (IIMs) have been studied within the framework of autoimmune diseases where skeletal muscle appears to have a passive role in the illness. However, persiting weakness even after resolving inflammation raises questions about the role that skeletal muscle plays by itself in these diseases. "Non-immune mediated" hypotheses have arisen to consider inner skeletal muscle cell processes as trigger factors in the clinical manifestations of IIMs. Read More

View Article and Full-Text PDF
January 2021

Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.

Mediators Inflamm 2020 26;2020:7948095. Epub 2020 Oct 26.

Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China.

Objective: Soluble CD206 (sCD206) is considered a macrophage activation marker, and a previous study proved it as a potential biomarker to predict the severity of anti-melanoma differentiation-associated gene 5- (anti-MDA-5-) positive dermatomyositis- (DM-) associated interstitial lung disease (ILD). To investigate the role of sCD206 in various subtypes of DM, we evaluated the serum level of sCD206 in patients with different myositis-specific autoantibodies besides anti-MDA-5 and clarified its clinical significance.

Methods: Commercial enzyme-linked immunosorbent assay kits were used to detect serum concentrations of sCD206 in 150 patients with DM and 52 healthy controls (HCs). Read More

View Article and Full-Text PDF
October 2020

Fulminant immune-mediated necrotising myopathy (IMNM) mimicking myocardial infarction with non-obstructive coronary arteries (MINOCA).

BMJ Case Rep 2020 Nov 2;13(11). Epub 2020 Nov 2.

Radiology Department, Royal United Hospital Bath NHS Trust, Bath, UK

A 74-year-old man, with inflammatory arthritis, recently commenced on adalimumab, presented with a 4-week history of left-sided chest pain, malaise and shortness of breath. Admission ECG showed age-indeterminate left bundle branch block. Troponin T was 4444 ng/L (normal range <15 ng/L) and acute coronary syndrome treatment was commenced. Read More

View Article and Full-Text PDF
November 2020

Cricopharyngeal bar and dermatomyositis: A cause of rapidly progressive dysphagia.

Int J Rheum Dis 2021 Jan 1;24(1):125-131. Epub 2020 Nov 1.

Private Rheumatology Practice, Campbelltown, NSW, Australia.

Background: Idiopathic inflammatory myopathies (IIM) are immune-mediated conditions that affect striated muscle, and are frequently associated with dysphagia. Dysphagia in these cases can be due to weakness of the muscles involved in swallowing or the presence of restrictive pharyngeal defects, such as cricopharyngeal bars. Treatment of dysphagia in IIM revolves around immunosuppressive therapies, and procedures to disrupt cricopharyngeus muscle when immunosuppressive therapies are unsuccessful. Read More

View Article and Full-Text PDF
January 2021

Complete Recovery from COVID-19 Bilateral Pneumonia in an Immunosuppressed Man with Immune-Mediated Necrotizing Myopathy.

Case Rep Rheumatol 2020 21;2020:8886324. Epub 2020 Oct 21.

Department of Internal Medicine, University of Michigan, 1500 E Medical Ctr Dr, Ann Arbor, MI 48109, USA.

Immune-mediated necrotizing myopathy (IMNM) is a rare form of idiopathic immune myopathy (IIM) that requires immunotherapies, including immunosuppressive medications, if severe. There is a paucity of data regarding outcomes of patients with immune-mediated polymyositis who continue immunosuppressive medications during the COVID-19 pandemic. This is the first reported case of COVID-19 in a patient with IMNM. Read More

View Article and Full-Text PDF
October 2020